Prevalence of Abuse Among Patients With Rheumatic Diseases

N

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Status

Enrolling

Conditions

Abuse
Abuse Neglect
Rheumatic Diseases

Treatments

Other: WHOQOL-BREF
Other: Family APGAR Questionnaire
Other: Depression, Anxiety and Stress Scale (DASS-21)
Other: Rheumatic diseases Mistreatment Scale (RDMS)
Other: Big Five Inventory
Other: Brief Resilient Coping Scale
Other: Health Assessment Questionnaire (HAQ)
Other: Routine assessment of patient index data 3 (RAPID-3)

Study type

Observational

Funder types

Other

Identifiers

NCT06233760
IRE3234

Details and patient eligibility

About

Patients with rheumatic diseases (RD) have a relevant representation in the adult population in Mexico. RD are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes. Regarding abuse in patients with RD, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability. The study aimed to identify the prevalence of abuse in patients with RD. The study will be conducted in two phases: the first one in which the GAS will be adapted for patients with RD, and this version will be validated in a population of our Institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with RD are explored.

Full description

Patients with rheumatic diseases (RD) have a relevant representation in the adult population in Mexico. RD are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes. In 1970, the phenomenon of abuse in geriatric patients was described for the first time as a phenomenon identified as a public health problem and an issue of human rights violation. In 2012 Giraldo-Rodríguez developed and validated the Geriatric Abuse Scale (GAS), an instrument that, with adequate psychometric properties, reported a prevalence of abuse of 10.28% in Mexico. Regarding abuse in patients with RD, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability. The study aimed to identify the prevalence of abuse in patients with RD. The study will be conducted in two phases: the first one in which the GAS will be adapted for patients with RD, and this version will be validated in a population of our Institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with RD are explored.

Enrollment

244 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a rheumatic disease diagnosis according to their primary rheumatologist who agree to participate

Exclusion criteria

  • Patients with a not confirmed rheumatic disease

Trial design

244 participants in 1 patient group

Patients with rheumatic diseases
Description:
All the rheumatic diseases outpatients from the National Institute of Medical Sciences
Treatment:
Other: Routine assessment of patient index data 3 (RAPID-3)
Other: Health Assessment Questionnaire (HAQ)
Other: Brief Resilient Coping Scale
Other: Big Five Inventory
Other: Rheumatic diseases Mistreatment Scale (RDMS)
Other: Depression, Anxiety and Stress Scale (DASS-21)
Other: Family APGAR Questionnaire
Other: WHOQOL-BREF

Trial contacts and locations

1

Loading...

Central trial contact

Virginia Ph Pascual-Ramos; Virginia Dr Pascual-Ramos

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems